UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

“Japan Diet” and Health—The Present and Future

Journal of Nutritional Science and Vitaminology, 2019/10/11, Vol.65(Supplement), pp.S29-S33

TERAMOTO, Tamio

2019

Volltextzugriff (PDF)

Is “The Japan Diet” Cardioprotective?

Journal of Atherosclerosis and Thrombosis, 2017/04/01, Vol.24(4), pp.388-389

Teramoto, Tamio

2017

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial

Circulation Journal, 2016/08/25, Vol.80(9), pp.1980-1987

2016

Volltextzugriff (PDF)

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan —2012 Version

Journal of Atherosclerosis and Thrombosis, 2013, Vol.20(6), pp.517-523

2013

Volltextzugriff (PDF)

Sitosterol prevents obesity-related chronic inflammation

Biochimica et biophysica acta. Molecular and cell biology of lipids, 2018-02, Vol.1863 (2), p.191-198

2018

Volltextzugriff (PDF)

Effects of Dietary Education Program for the Japan Diet on Cholesterol Efflux Capacity: A Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2022/06/01, Vol.29(6), pp.881-893

2022

Volltextzugriff (PDF)

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study

Circulation Journal, 2014, Vol.78(5), pp.1073-1082

2014

Volltextzugriff (PDF)

Effects of Nutrition Education Program for the Japan Diet on Serum LDL-Cholesterol Concentration in Patients with Dyslipidemia: A Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2021/10/01, Vol.28(10), pp.1035-1051

2021

Volltextzugriff (PDF)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

Journal of Atherosclerosis and Thrombosis, 2019/05/01, Vol.26(5), pp.408-431

2019

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)

The American journal of cardiology, 2016-07, Vol.118 (1), p.56-63

2016

Volltextzugriff (PDF)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

Journal of Atherosclerosis and Thrombosis, 2018/07/01, Vol.25(7), pp.580-592

2018

Volltextzugriff (PDF)

Diagnostic Criteria for Dyslipidemia: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012 Version

Journal of Atherosclerosis and Thrombosis, 2013, Vol.20(8), pp.655-660

2013

Volltextzugriff (PDF)

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State

Journal of Atherosclerosis and Thrombosis, 2017/06/01, Vol.24(6), pp.583-599

2017

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan

Journal of Atherosclerosis and Thrombosis, 2019/03/01, Vol.26(3), pp.282-293

2019

Volltextzugriff (PDF)

Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study

Circulation Journal, 2017/09/25, Vol.81(10), pp.1496-1505

2017

Volltextzugriff (PDF)

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Circulation Journal, 2017/06/23, Vol.81(7), pp.1029-1035

2017

Volltextzugriff (PDF)

Cholesterol 25-hydroxylation activity of CYP3A

Journal of lipid research, 2011-08, Vol.52 (8), p.1509-1516

2011

Volltextzugriff (PDF)

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　― A Retrospective Database Analysis

Circulation Journal, 2018/05/25, Vol.82(6), pp.1605-1613

2018

Volltextzugriff (PDF)

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects

International journal of clinical pharmacology and therapeutics, 2019-12, Vol.57 (12), p.575-589

2019

Volltextzugriff (PDF)

Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study

Journal of Atherosclerosis and Thrombosis, 2020/07/01, Vol.27(7), pp.683-694

2020

Volltextzugriff (PDF)

Effects of Nutrition Education Program for the Japan Diet on Serum Phospholipid Fatty Acid Compositions in Patients with Dyslipidemia: Re-analysis of Data from a Previous Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2023/12/01, Vol.30(12), pp.1849-1869

2023

Volltextzugriff (PDF)

Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Journal of Atherosclerosis and Thrombosis, 2007, Vol.14(2), pp.45-50

2007

Volltextzugriff (PDF)

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors

Hypertension research, 2016-02, Vol.39 (2), p.113-118

2016

Volltextzugriff (PDF)

Extending the “Lower is Better” Principle to Japanese and Possibly Other Asian Populations

Circulation (New York, N.Y.), 2018-05, Vol.137 (19), p.2010-2012

Teramoto, Tamio

2018

Volltextzugriff (PDF)

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Journal of cardiology, 2019-03, Vol.73 (3), p.218-227

2019

Volltextzugriff (PDF)

1 – 25 von 402

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(343)

Publikationsform

Artikel
(401)
Tagungsberichte
(1)

Sprache

Englisch
(342)
Japanisch
(173)

Erscheinungsjahr

n.n

Thema

Science & Technology
(190)
Humans
(189)
Life Sciences & Biomedicine
(187)
Male
(119)
Cardiovascular System & Cardiology
(109)
Female
(99)
Middle Aged
(86)
Peripheral Vascular Disease
(85)
Aged
(74)
Adult
(57)
Japan
(55)
Biological And Medical Sciences
(54)
Risk Factors
(50)
Cholesterol, Ldl - Blood
(41)
Cardiac & Cardiovascular Systems
(40)
Medical Sciences
(38)
Internal Medicine
(31)
Animals
(29)
Cholesterol, Hdl - Blood
(27)
Japan - Epidemiology
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

“Japan Diet” and Health—The Present and Future

Is “The Japan Diet” Cardioprotective?

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan —2012 Version

Sitosterol prevents obesity-related chronic inflammation

Effects of Dietary Education Program for the Japan Diet on Cholesterol Efflux Capacity: A Randomized Controlled Trial

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study

Effects of Nutrition Education Program for the Japan Diet on Serum LDL-Cholesterol Concentration in Patients with Dyslipidemia: A Randomized Controlled Trial

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

Diagnostic Criteria for Dyslipidemia: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012 Version

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Cholesterol 25-hydroxylation activity of CYP3A

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　― A Retrospective Database Analysis

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects

Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study

Effects of Nutrition Education Program for the Japan Diet on Serum Phospholipid Fatty Acid Compositions in Patients with Dyslipidemia: Re-analysis of Data from a Previous Randomized Controlled Trial

Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors

Extending the “Lower is Better” Principle to Japanese and Possibly Other Asian Populations

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Suchergebnisse filtern